



PRESS RELEASE

innate pharma

INNATE PHARMA UPDATED ON ITS NEXT MEETINGS WITH ANALYSTS AND INVESTORS

Marseilles, France, December 19, 2007

Innate Pharma (Euronext Paris: FR0010331421 – IPH), a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, announced it will participate to the following analyst and investor conferences during the month of January 2008:

- **Oddo Midcap Event, January 10-11, 2008, in Lyon, France:** Innate Pharma will present the company to French investors specialised in small and midcaps companies.
- **Biodata, January 22-23, 2008, in Geneva, Switzerland:** Innate Pharma will present the company to Swiss investors specialised in Biotech and Life Science.
- **First fund managers and biotechnology companies' meeting** organised by France Biotech and NYSE Euronext, **January 31, 2008, in Paris, France.**

Innate Pharma is committed to meet on a regular basis with the financial community. Investors can also find updated information on the company's website (www.innate-pharma.com) and contact the investor relations team by writing to investors@innate-pharma.com.



PRESS RELEASE

innate pharma

About Innate Pharma

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer and viral infections.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing immunotherapeutics market.

Based in Marseilles, France, Innate Pharma had 82 employees as of September 30, 2007.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information:

ISIN code FR0010331421

Ticker code IPH

Disclaimer

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Laure-Hélène Mercier,
Director, Investor Relations
Phone: +33 (0)4 88 66 05 87
lmercier@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Phone: +33 (0)1 41 22 06 59
Mob: +33 (0)6 64 18 99 59
caroline@alizerp.com

* with new mechanisms of action.